Press release
Insightful Analysis of the Nonalcoholic Steatohepatitis Therapeutics Market: Trends and Growth Forecast -2031
The Nonalcoholic Steatohepatitis (NASH) Therapeutics Market Report provides a comprehensive analysis of the global landscape, focusing on key drug types, market dynamics, and growth prospects from 2022 to 2031. This report offers valuable insights into emerging trends, market drivers, and challenges shaping the industry's trajectory.In 2021, the global nonalcoholic steatohepatitis therapeutics market reached a valuation of US$ 10.1 billion and is poised to grow at a robust CAGR of 13.6% from 2022 to 2031, surpassing a forecasted value of US$ 20.2 billion by 2031. This section provides an overview of market size, growth rate, and historical data analysis, laying the foundation for a detailed exploration.
Request Brochure of Nonalcoholic Steatohepatitis Therapeutics Market Research Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7691
Analysts' Viewpoint on Global Nonalcoholic Steatohepatitis Therapeutics Market Scenario
With no FDA-approved drug for NASH treatment, pharmaceutical companies are expected to introduce pipeline drugs to address this silent liver disease. The market is driven by the global rise in diabetes and obesity prevalence rates, coupled with increased awareness of available treatments. Manufacturers are engaging in clinical trials, particularly for Elafibranor, to enhance treatment efficacy and credibility. Strategic mergers, acquisitions, and research collaborations are recommended to launch innovative products for NASH treatment.
Overview of Global Nonalcoholic Steatohepatitis Therapeutics Market
NAFLD and its advanced form, NASH, pose significant health challenges globally. With obesity and insulin resistance as major contributing factors, the demand for effective treatments is escalating. NASH progression to liver cirrhosis underscores the urgent need for therapeutic interventions, driving market growth.
Surge in Prevalence of Nonalcoholic Steatohepatitis Disease Globally
NASH, a type of liver disease prevalent among non-alcoholic individuals, is characterized by liver fat deposition and inflammation. The increasing incidence of NASH is driving demand for therapeutics, with multiple drugs being launched to alleviate the disease burden. However, poor diagnostics and lack of proper diagnostic techniques pose challenges to market growth.
Rise in Investments in Drug Research and Development to Drive Global Market
Pharmaceutical companies are intensifying research and development efforts to address the unmet need for NASH therapeutics. Outsourcing of drug development processes and increased investment in R&D are facilitating innovation and accelerating drug discovery timelines. Despite cost-cutting pressures, investments in drug research remain robust, driven by the growing burden of NASH globally.
Increase in Number of People with Diabetes and Obesity to Propel Global Market
The escalating prevalence of diabetes, obesity, and high cholesterol levels is contributing to the rise in NAFLD and NASH cases globally. Urgent treatment methods are required to manage these conditions effectively, driving demand for NASH therapeutics. Advancements in technology and ongoing research efforts aim to develop more effective treatment options to address the growing disease burden.
Request for Analysis of COVID-19 Impact on Nonalcoholic Steatohepatitis Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=7691
Impact of COVID-19 on Global Nonalcoholic Steatohepatitis Therapeutics Market
The COVID-19 pandemic has impacted healthcare services, leading to a decline in NASH therapy, detection, and follow-up. Disruptions in drug clinical trials have further compounded challenges in NASH management. However, the etiology of COVID-19 liver injury has underscored the importance of liver health, highlighting the need for continued research and innovation in NASH therapeutics.
Elafibranor Reduces Liver Fat, Gains Preference for Treatment of NASH
Elafibranor, among other potential phase III candidates, emerges as a key player in the NASH therapeutics market. Its ability to reduce liver fat and positive outcomes in phase 3 clinical trials position it as a promising treatment option. With no existing medicine for NASH, Elafibranor holds significant market potential, driving its preference among healthcare providers and patients.
Cost-cutting Pressure from Regulatory Bodies to Restrain Market Growth
Government initiatives aimed at cost-cutting, coupled with increasing pressure from insurers and payers, pose challenges to market growth. Pharmaceutical companies face pricing pressures and demand for cost-effective treatment options, particularly in developing countries. Addressing these concerns while ensuring continued innovation is crucial for sustained market growth.
Regional Outlook of Global Nonalcoholic Steatohepatitis Therapeutics Market
North America dominates the global NASH therapeutics market, driven by a high prevalence of diabetes, obesity, and lifestyle changes. Europe, particularly countries like Italy, Spain, Germany, the U.K., and France, also presents lucrative opportunities for NASH therapeutics due to rising disease prevalence. Strategic market expansion efforts are recommended to capitalize on regional growth prospects.
Analysis of Key Players in Global Nonalcoholic Steatohepatitis Therapeutics Market
The global NASH therapeutics market is characterized by a highly fragmented landscape, with key players focusing on product innovation and strategic collaborations. Profiles of leading companies such as Intercept Pharmaceuticals, GENFIT SA, and Gilead Sciences offer insights into their strategies and market positioning. The competitive landscape section provides a comprehensive overview of key players and their market share analysis.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Insightful Analysis of the Nonalcoholic Steatohepatitis Therapeutics Market: Trends and Growth Forecast -2031 here
News-ID: 3379868 • Views: …
More Releases from Transparency Market Research

Global Solar Powered Agricultural Dryer Market to Exceed USD 2.4 Billion by 2031 …
The global solar powered agricultural dryer market, valued at US$ 1.6 billion in 2022, is projected to grow at a CAGR of 5.8% from 2023 to 2031, reaching US$ 2.4 billion by the end of 2031. Rising investments in renewable energy, growing awareness of sustainable agricultural practices, and the rapid expansion of the agricultural sector driven by population growth are key factors fueling market growth.
Uncover essential discoveries and trends from…

Technetium-99m Market Forecast 2034: Rising Demand for Diagnostic Imaging and Ra …
The global Technetium‐99m Market was valued at US$ 6.0 Billion in 2023 and is projected to grow at a CAGR of 3.3% from 2024 to 2034, surpassing US$ 8.6 Billion by the end of the forecast period. Advancements in nuclear imaging infrastructure, government-backed healthcare initiatives, and an increasing demand for precise diagnostic procedures are fueling this growth.
Discover essential conclusions and data from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=77100
Analysts' Viewpoint
The Technetium‐99m…

Equine Diagnostic Services Market Outlook 2030: From US$ 168 Million in 2019 to …
The global Equine Diagnostic Services Market, valued at approximately US$ 168 million in 2019, is projected to expand at a compound annual growth rate (CAGR) of ~5% from 2020 to 2030, reaching around US$ 280 million by 2030. Equine diagnostic services, encompassing tests like genetic, infectious disease, and imaging diagnostics, are critical for managing horse health in veterinary hospitals, clinics, and mobile settings. The market is driven by increasing equine…

Digital Printing Market to Reach USD 54.4 Billion by 2034, Growing at a CAGR of …
The digital printing market is experiencing strong growth, driven by rapid technological advancements, rising demand for personalized and on-demand printing, and an increasing focus on sustainable solutions. Digital printing allows for the direct transfer of digital files onto a wide range of substrates, offering high-resolution output with greater speed and flexibility. Its adaptability has led to broad adoption across industries such as packaging, textiles, publishing, and advertising-sectors where customization, efficiency,…
More Releases for NASH
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…